SpaceX Q2 Earnings on Aug. 4 Set Stage for Historic Insider Share Unlock 
DeepSeek Eyes $74 Billion Valuation Ahead of Planned China IPO 
Mikron H1 2026 Sales Fall 5.9% as Automation Weakness Weighs on Profit 
Belimo H1 Sales Surge as AI Data Center Cooling Drives More Than Half of Growth 
GameStop Raises eBay Stake to 9.8% as Ryan Cohen Pushes $56 Billion Takeover Bid 
Netflix Stock Drops After Weak Q3 Outlook Overshadows Mixed Q2 Earnings 
Samsung Cuts U.S. Consumer Electronics Jobs as Headquarters Moves to Texas 
Lockheed Martin Unveils Lower-Cost Patriot ACE Interceptor to Meet Rising Air Defense Demand 
KKR, AEW Seek China Property Sales as Commercial Real Estate Slump Deepens 
Volvo Cars Q2 Profit Falls as Automaker Bets on EX60 EV to Drive Recovery 
SpaceX Eyes Pentagon AI Deal as Cloud Pricing Strategy Pressures CoreWeave 
Ryanair Warns Summer Airfares May Stay Lower as Quarterly Profit Misses Estimates 
SpaceX Targets Thursday Launch for Starship's 13th Test Flight After Last-Minute Delay 
Why Maruti Suzuki Is Losing Market Share in India as SUVs and Premium Features Gain Popularity 
Samsung Biologics Launches $1.81 Billion Bid to Acquire PolyPeptide 
KPMG Australia Appoints John Sams as CEO Following Audit Leak Scandal 
ASML Trillion-Dollar Valuation: Can Europe’s AI Chip Giant Reach the Historic Milestone? 
Celltrion Pharmaceutical company has finally completed merging with its Celltrion Healthcare affiliate. This comes after the board of directors has given the “go-ahead” signal for the merger on Thursday, Dec. 28.
The unification of Celltrion and Celltrion Healthcare happened three years after the plan was first announced by the former. According to Korea Joongang Daily, the newly formed entity, following the completion of the affiliation, will then proceed to go into another merger process, this time with Celltrion Pharm. This second deal is expected to be completed sometime next year.
New Unified Entity to Enter Another Merger Deal
The new company was formed after Celltrion and Celltrion Healthcare were successfully consolidated into one entity. This will be merged with Celltrion Pharma, and the resulting new organization will have Celltrion Holdings as its largest shareholder with a 21.5% share.
In any case, it was mentioned that Celltrion’s founder and chairman, Seo Jung Jin, still has a 98.1% stake in the group’s holdings firm. As three firms are being consolidated with this succession of mergers, the company is aiming to reach KRW2 trillion won or about $9 billion in annual revenue by the year 2030.
“Celltrion was able to secure massive funds through the merger and will invest them in our new future growth engines like biosimilars, new drug development and mergers and acquisitions,” Celltrion commented.
Appointment of Three CEOs for the Merged Company
The integrated Celltrion company is set to be managed by three chief executive officers. Korea’s Alphabiz reported that the appointed executives include Ki Woo Sung, who will supervise the manufacturing and development division; Kim Hyung Ki, who will be assigned to manage the global sales unit; and Seo Jin Seok, who will become head of the business management unit.
Celltrion will start operating as a representative system for the three chiefs soon.
Photo by: Celltrion Media Center
